Nitrofurantoin Iasis (Nitrofurantoin)

Nitrofurantoin is reduced by bacterial enzymes to reactive metabolites that damage bacterial DNA, ribosomal proteins, and enzymes involved in carbohydrate metabolism. This multi‑target attack disrupts cell wall synthesis and essential metabolic pathways, leading to bacterial death, especially in the urinary tract where the drug is highly concentrated.

The specific dose and duration of Nitrofurantoin Iasis are determined by the prescribing clinician based on the patient’s infection severity, renal function, and other clinical factors. Healthcare providers set the appropriate regimen according to current guidelines and individual patient needs.

Nitrofurantoin is classified as Pregnancy Category B, indicating no evidence of risk in animal studies but limited human data. It is generally avoided in late pregnancy due to potential fetal hemolysis. Use during breastfeeding is considered compatible, but clinicians should weigh benefits against possible risks.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After verification of trade or institutional credentials, the sales team will provide pricing, availability, shipping details, and necessary import documentation.

Compared with agents such as trimethoprim‑sulfamethoxazole or fluoroquinolones, nitrofurantoin offers a narrow spectrum focused on common uropathogens and achieves high urinary concentrations with minimal systemic exposure. It is often preferred for uncomplicated infections due to lower resistance rates, though it is unsuitable for patients with significant renal impairment.

Nitrofurantoin Iasis should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from moisture, excessive heat, and direct sunlight to maintain stability and potency throughout its shelf life.

Nitrofurantoin Iasis is administered orally, typically as a tablet taken with a full glass of water. It is usually recommended to be taken with food to improve gastrointestinal tolerance, unless the prescribing information advises otherwise.

Serious risks include pulmonary toxicity (interstitial lung disease), hepatic injury, hemolytic anemia in patients with G6PD deficiency, severe allergic reactions, peripheral neuropathy, and blood dyscrasias such as agranulocytosis. Patients should be monitored for any signs of these conditions and seek immediate medical attention if they occur.

Nitrofurantoin Iasis is contraindicated in patients with severe renal impairment (creatinine clearance <30 mL/min), known hypersensitivity to nitrofurantoin, G6PD deficiency, and in late pregnancy. Caution is also advised for elderly patients and those with a history of pulmonary or hepatic disease.